top of page

Avanti Biosciences is a dynamic biotechnology company situated within the Johnson & Johnson Innovation – JLABS incubator in San Diego. Our mission is to revolutionize the treatment landscape for patients suffering from debilitating diseases, with a particular focus on fibrotic disorders such as idiopathic pulmonary fibrosis (IPF), as well as neurodegenerative conditions like Alzheimer's (AD) and Parkinson's disease (PD), inflammatory diseases, and metabolic disorders such as nonalcoholic fatty liver disease (NAFLD).

Our research strategy is centered on the discovery and development of innovative therapies that harness the power of natural products. By enhancing the bioavailability and selectivity of new chemical entities (NCEs), we aim to create more effective treatments that can precisely target complex diseases.

Avanti's scientific founders are globally recognized leaders in drug discovery and clinical development, boasting an impressive track record of transforming cutting-edge research into groundbreaking therapeutics. Their expertise and insights are instrumental in guiding our pursuit of novel solutions for unmet medical needs.

The pioneering work of Avanti Biosciences holds promise for a broad spectrum of therapeutic applications beyond our current focus areas, potentially offering new hope to patients across various medical fields.

At a Glance
  • Private R&D stage biotech company
  • Research focused on the treatment of unmet medical needs like:
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Nonalcoholic steatohepatitis (NASH)  
    • Alzheimer's Disease (AD)
    • Down Syndrome (DS)
  • Technology based on natural catechins that are major components of green tea 
  • Research is funded through private funds and NIH grants
bottom of page